The 15-Year Standard in HER2-Positive Gastric Cancer Is Changing With Zanidatamab! NEJM Article

Is the 15-Year Standard in HER2-Positive Gastroesophageal Cancer Changing? Zanidatamab Gains Strength With NEJM Data

The Long Wait in HER2-Positive Gastroesophageal Cancer

Gastroesophageal adenocarcinomas are a group of diseases encompassing gastric, gastroesophageal junction and esophageal adenocarcinomas that often progress rapidly at an advanced stage. In a proportion of these tumors, HER2 positivity is detected. HER2 positivity suggests, on the one hand, that the tumor biology may be more aggressive and, on the other, opens a strong gateway to targeted treatment.

The arrival of HER2-targeted treatment with trastuzumab in this field was an important advance in the history of gastric cancer. Over time, however, two main problems became clearer. First, HER2 expression in gastric and esophageal adenocarcinomas may not be as homogeneous as in breast cancer. Second, targeting HER2 at a single site may remain vulnerable to resistance developing over time. New agents were therefore needed that could bind more strongly, target the HER2 receptor more effectively and also engage the immune system.

Zanidatamab is a new-generation HER2-targeted antibody developed to meet this need. This is also where the importance of HERIZON-GEA-01 lies: the study is not merely testing a new drug; it asks whether a stronger HER2-targeting strategy can replace the trastuzumab-centered standard used for years in HER2-positive gastroesophageal cancer.

What Is Tislelizumab and Why Is It Included in This Combination?

Tislelizumab, as a PD-1 inhibitor, is an immunotherapy in this class. PD-1 is a checkpoint found on T cells that restrains the immune response. Cancer cells can use this braking mechanism to evade the immune system. PD-1 inhibitors aim to remove the brake and reactivate T cells against the tumor.

Immunotherapy has become increasingly important in gastroesophageal cancers in recent years, but it does not have the same effect in every patient. Combining HER2-targeted treatment with immunotherapy is a biologically interesting strategy. An antibody that binds strongly to HER2 can create a marker on the tumor cell that the immune system can recognize; PD-1 blockade can help this immune response continue more effectively.

A Global Phase 3 Comparison in 914 Patients

HERIZON-GEA-01 is an open-label, randomized phase 3 study conducted in patients with advanced gastroesophageal adenocarcinoma who had not received previous systemic treatment and whose HER2-positive status was centrally confirmed. Patients were allocated to three arms in a 1:1:1 ratio:

In the study, progression-free survival (PFS) and overall survival (OS) were the two primary endpoints. Median follow-up was reported as 25,9 months. This is a meaningful follow-up duration for assessing not only early response rates but also the treatment's effects on disease control and lifespan.

Both Zanidatamab Arms Are Superior in Progression-Free Survival

The clearest result was seen in progression-free survival. In both the zanidatamab + tislelizumab + chemotherapy and zanidatamab + chemotherapy arms, a median PFS of 12,4 months was recorded. In the control arm, meaning patients receiving trastuzumab + chemotherapy, a median PFS of 8,1 months was found.

The Strongest Overall Survival Signal Is in the Triple Combination

Overall survival results require more careful interpretation. In the interim analysis, the superiority of the triple combination was demonstrated statistically, whereas the zanidatamab + chemotherapy arm showed a numerical advantage without reaching the threshold for statistical significance.

As Efficacy Increases, the Burden of Side Effects Also Requires Close Monitoring

One of the most important messages from HERIZON-GEA-01 is that, despite the marked increase in efficacy, gastrointestinal side effects in particular require careful management. The rate of grade 3 or higher side effects was higher with the triple combination.

A Candidate for a New Standard: Could Zanidatamab Replace Trastuzumab?

HERIZON-GEA-01 seeks answers to two separate questions in HER2-positive advanced gastroesophageal adenocarcinoma: first, could zanidatamab provide a better HER2-targeted backbone than trastuzumab? Second, does adding a PD-1 inhibitor to this backbone further extend lifespan?

The PFS results answer the first question with a strong “yes.” PFS reached 12,4 months in both zanidatamab arms and was markedly better than in the trastuzumab arm. The clearest overall survival evidence was seen with the triple combination. Although median OS of 24,4 months in the zanidatamab + chemotherapy arm was numerically better, it did not reach the threshold for statistical significance in this interim analysis. More mature survival analyses should therefore be awaited for this arm.

Current Status for the FDA and Clinical Use

Zanidatamab is an agent that has previously received accelerated approval in the United States for HER2-positive biliary tract cancer. For first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, the FDA application for zanidatamab combinations has been accepted for priority review. The PDUFA target decision date, 25 August 2026, has been announced. These data therefore have the potential to change clinical practice, but approval and reimbursement status should be checked separately for each country.

A New Threshold in HER2-Positive Gastric and Gastroesophageal Cancer

HERIZON-GEA-01 shows that the treatment paradigm in HER2-positive advanced gastroesophageal adenocarcinoma is on the verge of changing. Trastuzumab + chemotherapy was the main standard for many years; however, these phase 3 data published in NEJM clearly demonstrate that zanidatamab-based treatments provide longer disease control.

The strongest clinical message comes from the triple combination: zanidatamab + tislelizumab + chemotherapyincreased median progression-free survival from 8,1 to 12,4 months and median overall survival from 19,2 to 26,4 months. This suggests that advanced HER2-positive gastroesophageal cancer is witnessing the arrival not merely of a new drug, but of a new-generation form of HER2 targeting.

Nevertheless, this success does not lessen the importance of side effect management. Gastrointestinal toxicities, particularly diarrhea, should be recognized early and managed actively. In the coming period, more mature survival analyses, subgroup results, PD-L1 biomarker details and country-specific approval/reimbursement decisions will determine how this treatment becomes established in everyday practice.